A practical reference on anti-doping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
== Principle of operations == In peptide biosensors, peptides serve as the selective recognition element due to their amino acid sequence, which also accounts for their tailored binding affinity and specificity towards various analytes. When the analyte interacts with the peptide recognition elements via non-covalent interactions, this interaction produces a change that can be transduced into a measurable signal. Peptides on their own cannot generate a quantifiable signal after binding events with the analytes, they must be bio-conjugated to signal markers. Common detection strategies include optical methods such as fluorescence resonance energy transfer (FRET), electrochemical outputs such as change in current, impedance, or potential, and sometimes mechanical or piezoelectric signals if the peptide-analyte binding alters mass or surface properties. These methods are commonly employed due to their sensitivity and compatibility with small peptide-based interfaces
Oxycodone has a hydroxy group at carbon-14 (codeine has just a hydrogen in its place) Oxycodone has a 7,8-dihydro feature. Codeine has a double bond between those two carbons; and Oxycodone has a carbonyl group (as in ketones) in place of the hydroxyl group of codeine. It is also similar to hydrocodone, differing only in that it has a hydroxyl group at carbon-14.
Omacetaxine mepesuccinate (INN; trade name Synribo; formerly named as homoharringtonine or HHT) is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). Omacetaxine approval in US is discontinued (August 2024)[1][2] and is no longer recommended for treatment of CML (as of NCCN CML guidance 3.2025) [3]. HHT is a natural plant alkaloid derived from Cephalotaxus fortunei. HHT and related compound esters of cephalotaxine were described first in 1970, and were the subject of intensive research efforts by Chinese investigators to clarify their role as anticancer and antileukemic agents from the 1970s until the present. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).
high-affinity glutamate and neutral amino acid transporter (SLC1A1, SLC1A2, SLC1A3, SLC1A4, SLC1A5, SLC1A6, SLC1A7) facilitative GLUT transporter (SLC2A1, SLC2A2, SLC2A3, SLC2A4, SLC2A5, SLC2A6, SLC2A7, SLC2A8, SLC2A9, SLC2A10, SLC2A11, SLC2A12, SLC2A13, SLC2A14) heavy subunits of heterodimeric amino acid transporters (SLC3A1, SLC3A2) bicarbonate transporter (SLC4A1, SLC4A2, SLC4A3, SLC4A4, SLC4A5, SLC4A6, SLC4A7, SLC4A8, SLC4A9, SLC4A10, SLC4A11) sodium glucose cotransporter (SLC5A1, SLC5A2, SLC5A3, SLC5A4, SLC5A5, SLC5A6, SLC5A7, SLC5A8, SLC5A9, SLC5A10, SLC5A11, SLC5A12) sodium- and chloride-dependent sodium:neurotransmitter symporters (SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC6A5, SLC6A6, SLC6A7, SLC6A8, SLC6A9, SLC6A10, SLC6A11, SLC6A12, SLC6A13, SLC6A14, SLC6A15, SLC6A16, SLC6A17, SLC6A18, SLC6A19, SLC6A20) cationic amino acid transporter/glycoprotein-associated cationic amino acid transporters (SLC7A1, SLC7A2, SLC7A3, SLC7A4) glycoprotein-associated/light or catalytic subunits of heterodimeric amino acid transporters (SLC7A5, SLC7A6, SLC7A7, SLC7A8, SLC7A9, SLC7A10, SLC7A11, SLC7A13, SLC7A14) Na+/Ca2+ exchanger (SLC8A1, SLC8A2, SLC8A3) Na+/H+ exchanger (SLC9A1, SLC9A2, SLC9A3, SLC9A4, SLC9A5, SLC9A6, SLC9A7, SLC9A8, SLC9A9, SLC9A10, SLC9A11, SLC9B1, SLC9B2) sodium bile salt cotransport (SLC10A1, SLC10A2, SLC10A3, SLC10A4, SLC10A5, SLC10A6, SLC10A7) proton coupled metal ion transporter (SLC11A1, SLC11A2) electroneutral cation-Cl cotransporter (SLC12A1, SLC12A2, SLC12A3, SLC12A4, SLC12A5, SLC12A6, SLC12A7, SLC12A8, SLC12A9) Na+-sulfate/carboxylate cotransporter (SLC13A1, SLC13A2, SLC13A3, SLC13A4, SLC13A5) urea transporter (SLC14A1, SLC14A2) proton oligopeptide cotransporter (SLC15A1, SLC15A2, SLC15A3, SLC15A4) monocarboxylate transporter (SLC16A1, SLC16A2, SLC16A3, SLC16A4, SLC16A5, SLC16A6, SLC16A7, SLC16A8, SLC16A9, SLC16A10, SLC16A11, SLC16A12, SLC16A13, SLC16A14) vesicular glutamate transporter (SLC17A1, SLC17A2, SLC17A3, SLC17A4, SLC17A5, SLC17A6, SLC17A7, SLC17A8, SLC17A9) vesicular amine transporter (SLC18A1, SLC18A2, SLC18A3) folate/thiamine transporter (SLC19A1, SLC19A2, SLC19A3) type III Na+-phosphate cotransporter (SLC20A1, SLC20A2) organic anion transporting subfamily 1 (SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1) subfamily 2 (SLCO2A1, SLCO2B1) subfamily 3 (SLCO3A1) subfamily 4 (SLCO4A1, SLCO4C1) subfamily 5 (SLCO5A1) subfamily 6 (SLCO6A1) organic cation/anion/zwitterion transporter (SLC22A1, SLC22A2, SLC22A3, SLC22A4, SLC22A5, SLC22A6, SLC22A7, SLC22A8, SLC22A9, SLC22A10, SLC22A11, SLC22A12, SLC22A13, SLC22A14, SLC22A15, SLC22A16, SLC22A17, SLC22A18, SLC22A18AS, SLC22A19, SLC22A20, SLC22A23, SLC22A24, SLC22A25, SLC22A31) Na+-dependent ascorbic acid transporter (SLC23A1, SLC23A2, SLC23A3, SLC23A4) Na+/(Ca2+-K+) exchanger (SLC24A1, SLC24A2, SLC24A3, SLC24A4, SLC24A5, SLC24A6) mitochondrial carrier (SLC25A1, SLC25A2, SLC25A3, SLC25A4, SLC25A5, SLC25A6, UCP1(SLC25A7), UCP2(SLC25A8), UCP3(SLC25A9), SLC25A10, SLC25A11, SLC25A12, SLC25A13, SLC25A14, SLC25A15, SLC25A16, SLC25A17, SLC25A18, SLC25A19, SLC25A20, SLC25A21, SLC25A22, SLC25A23, SLC25A24, SLC25A25, SLC25A26, SLC25A27, SLC25A28, SLC25A29, SLC25A30, SLC25A31, SLC25A32, SLC25A33, SLC25A34, SLC25A35, SLC25A36, SLC25A37, SLC25A38, SLC25A39, SLC25A40, SLC25A41, SLC25A42, SLC25A43, SLC25A44, SLC25A45, SLC25A46), SLC25A47, SLC25A48, MTCH1(SLC25A49), MTCH2(SLC25A50), SLC25A51, SLC25A52, SLC25A53 multifunctional anion exchanger (SLC26A1, SLC26A2, SLC26A3, SLC26A4, SLC26A5, SLC26A6, SLC26A7, SLC26A8, SLC26A9, SLC26A10, SLC26A11) fatty acid transport proteins (SLC27A1, SLC27A2, SLC27A3, SLC27A4, SLC27A5, SLC27A6) Na+-coupled nucleoside transport (SLC28A1, SLC28A2, SLC28A3) facilitative nucleoside transporter (SLC29A1, SLC29A2, SLC29A3, SLC29A4) zinc transporter (SLC30A1, SLC30A2, SLC30A3, SLC30A4, SLC30A5, SLC30A6, SLC30A7, SLC30A8, SLC30A9, SLC30A10) copper transporter (SLC31A1, SLC31A2) vesicular inhibitory amino acid transporter (SLC32A1) Acetyl-CoA transporter (SLC33A1) type II Na+-phosphate cotransporter (SLC34A1, SLC34A2, SLC34A3) nucleotide-sugar transporter subfamily A (SLC35A1, SLC35A2, SLC35A3, SLC35A4, SLC35A5) subfamily B (SLC35B1, SLC35B2, SLC35B3, SLC35B4) subfamily C (SLC35C1, SLC35C2) subfamily D (SLC35D1, SLC35D2, SLC35D3) subfamily E (SLC35E1, SLC35E2A, SLC35E2B, SLC35E3, SLC35E4) subfamily F (SLC35F1, SLC35F2, SLC35F3, SLC35F4, SLC35F5) subfamily G (SLC35G1, SLC35G3, SLC35G4, SLC35G5, SLC35G6) proton-coupled amino acid transporter (SLC36A1, SLC36A2, SLC36A3, SLC36A4) sugar-phosphate/phosphate exchanger (SLC37A1, SLC37A2, SLC37A3, SLC37A4) System A & N, sodium-coupled neutral amino acid transporter (SLC38A1, SLC38A2, SLC38A3, SLC38A4, SLC38A5, SLC38A6, SLC38A7, SLC38A8, SLC38A9, SLC38A10, SLC38A11) metal ion transporter (SLC39A1, SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A8, SLC39A9, SLC39A10, SLC39A11, SLC39A12, SLC39A13, SLC39A14) basolateral iron transporter (SLC40A1) MgtE-like magnesium transporter (SLC41A1, SLC41A2, SLC41A3) Ammonia transporter (RHAG(SLC42A1), RHBG(SLC42A2), RHCG(SLC42A3)) Na+-independent, system-L like amino acid transporter (SLC43A1, SLC43A2, SLC43A3) Choline-like transporter (SLC44A1, SLC44A2, SLC44A3, SLC44A4, SLC44A5) Putative sugar transporter (SLC45A1, SLC45A2, SLC45A3, SLC45A4) Folate transporter (SLC46A1, SLC46A2, SLC46A3) multidrug and toxin extrusion (SLC47A1, SLC47A2) Heme transporter family (SLC48A1) Heme transporter (FLVCR1(SLC49A1), FLVCR2(SLC49A2), SLC49A3, SLC49A4) Sugar efflux transporters of the SWEET family (SLC50A1) Transporters of steroid-derived molecules (SLC51A, SLC51B) Riboflavin transporter family RFVT/SLC52 (SLC52A1, SLC52A2, SLC52A3) Phosphate carriers (XPR1(SLC53A1)) Mitochondrial pyruvate carriers (MPC1(SLC54A1), MPC2(SLC54A2), MPC1L(SLC54A3)) Mitochondrial cation/proton exchangers (LETM1(SLC55A1), LETM2(SLC55A2), LETMD1(SLC55A3)) Sideroflexins (SFXN1(SLC56A1), SFXN2(SLC56A2), SFXN3(SLC56A3), SFXN4(SLC56A4), SFXN5(SLC56A5)) NiPA-like magnesium transporter family (NIPA1(SLC57A1), NIPA2(SLC57A2), NIPAL1(SLC57A3), NIPAL2(SLC57A4), NIPAL3(SLC57A5), NIPAL4(SLC57A6)) MagT-like magnesium transporter family (MAGT1(SLC58A1), TUSC3(SLC58A2)) Sodium-dependent lysophosphatidylcholine symporter family (MFSD2A(SLC59A1), MFSD2B(SLC59A2)) Glucose transporters (MFSD4A(SLC60A1), MFSD4B(SLC60A2)) Molybdate transporter family (MFSD5(SLC61A1)) Pyrophosphate transporters (ANKH(SLC62A1)) Sphingosine-phosphate transporters (SPNS1(SLC63A1), SPNS2(SLC63A2), SPNS3(SLC63A3)) Golgi Ca2+/H+ exchangers (TMEM165(SLC64A1)) NPC-type cholesterol transporters (NPC1(SLC65A1), NPC1L1(SLC65A2)) Cationic amino acid exporters (SLC66A1, SLC66A2, SLC66A3, CTNS(SLC66A4), MPDU1(SLC66A5))
Sources: en.wikipedia.org
=== Phylogeny === The cladogram presented here illustrates the "family tree" of reptiles, and follows a simplified version of the relationships found by M.S. Lee, in 2013. All genetic studies have supported the hypothesis that turtles are diapsids; some have placed turtles within Archosauromorpha, though a few have recovered turtles as Lepidosauromorpha instead. The cladogram below used a combination of genetic (molecular) and fossil (morphological) data to obtain its results.
=== College and service years === Banting finally passed examinations in July 1910. He stated on his application to university that he wished to be a teacher, although he also harbored aspirations of becoming a doctor. He toured the Canadian West for the summer, traveling to Winnipeg and Calgary, before enrolling at the University of Toronto, where he entered the General Arts course at Victoria College. Despite hard work, Banting failed his first year, but decided to become a doctor and returned to repeat the year. He petitioned to join the medical program in February 1912 and was accepted. In September, he dropped out of Victoria College to begin medical school at the University of Toronto. Banting established himself in medical school by working diligently. His roommate, Sam Graham, remembered him for studying late into the night. Besides being a successful rugby player, however, he was otherwise undistinguished. His grades—now without the burden of language courses—saw a marked improvement, averaging approximately a B, an above-average score. Summers were spent returning to work at the farm. At Toronto's Faculty of Medicine, Banting specialised in surgery. At the onset of World War I, Banting, along with most Canadian men, sought to enlist in the army. He attempted to enter the Canadian Expeditionary Force on August 16, 1914, the day after Canada's declaration of war, and then again in October, but was refused twice due to poor vision.
=== Nanomaterials === Nanoparticles are used for several antimicrobial applications due to their extraordinary behavior. More studies are being carried out on the ability of nanomaterials to be utilized for antimicrobial coatings due to their highly reactive nature.
Digital agriculture, sometimes known as smart farming or e-agriculture, are tools that digitally collect, store, analyze, and share electronic data and/or information in agriculture. The Food and Agriculture Organization of the United Nations has described the digitalization process of agriculture as the digital agricultural revolution. Other definitions, such as those from the United Nations Project Breakthrough, Cornell University, and Purdue University, also emphasize the role of digital technology in the optimization of food systems. Digital agriculture includes (but is not limited to) precision agriculture. Unlike precision agriculture, digital agriculture impacts the entire agri-food value chain before, during, and after on-farm production. Therefore, on-farm technologies like yield mapping, GPS navigation, and tracking, and variable-rate application, fall under the domain of precision agriculture and digital agriculture. On the other hand, digital technologies involved in e-commerce platforms, e-extension services, warehouse receipt systems, blockchain-enabled food traceability systems, tractor rental apps, etc. fall under the umbrella of digital agriculture but not precision agriculture.
== SI == si – (s) Sinhala language (ISO 639-1 code) Si – (s) Silicon SI (s) Slovenia (ISO 3166 and FIPS 10-4 country code digram) (i) Socialist International Sports Illustrated Système International (French, International System of Units) SIA – (s) Singapore Airlines (ICAO code) SIA – (i) Survivors of Incest Anonymous SIAM – (i) Society for Industrial and Applied Mathematics SIC – (a) Standard Industrial Classification SICS – (a/i) Swedish Institute of Computer Science SIDS – (a) Sudden infant death syndrome SIDU – (i) select, insert, delete, update. See Create, read, update and delete SIF – (i) Selective Identification Feature SIFF – (i) Successor IFF SIG (i) Schweizerische Industrie Gesellschaft (German, "Swiss Industry Company"). See also SIG Sauer, a firearms manufacturer spun off from the aforementioned company in 2000.
Sources: en.wikipedia.org
=== Infection === The use of greater amount of red blood cells has been suggested to increase the risk of infections, not only transfusion-transmitted infections, but also due to a phenomenon known as transfusion-related immunomodulation (TRIM). TRIM may be caused by macrophages and their byproducts. In those who were given red blood cells only with significant anemia ("restrictive" strategy), serious infection rates were 10.6% while in those who were given red blood at milder levels of anemia ("liberal" strategy), serious infection rates were 12.7%. On rare occasions, blood products are contaminated with bacteria. This can result in a life-threatening infection known as transfusion-transmitted bacterial infection. The risk of severe bacterial infection is estimated, as of 2020, at about 1 in 2,500 platelet transfusions, and 1 in 2,000,000 red blood cell transfusions. Blood product contamination, while rare, is still more common than actual infection. The reason platelets are more often contaminated than other blood products is that they are stored at room temperature for short periods of time. Contamination is also more common with longer duration of storage, especially if that means more than 5 days. Sources of contaminants include the donor's blood, donor's skin, phlebotomist's skin, and containers. Contaminating organisms vary greatly, and include skin flora, gut flora, and environmental organisms. There are many strategies in place at blood donation centers and laboratories to reduce the risk of contamination.
Charcot–Marie–Tooth (CMT) disease is a genetically heterogeneous disorder, meaning that it can be caused by mutations in many different genes. To date, dozens of genes have been linked to various forms of CMT, reflecting the complexity of its molecular basis. As a result, CMT is classified into several major types, such as CMT1, CMT2, CMT4, CMTX, and intermediate forms, based on the pattern of inheritance and whether the primary defect affects the myelin sheath or the axon. CMT1 involves demyelination and is most caused by duplication of the PMP22 gene, while CMT2 is primarily axonal and frequently linked to mutations in genes such as MFN2 or NEFL. X-linked and autosomal recessive forms, like CMTX and CMT4, are also recognized and often associated with more severe or early-onset symptoms. Each type is further divided into subtypes, defined by the specific gene that is mutated. This genetic classification helps guide diagnosis, prognosis, and, potentially, the development of targeted therapies.
West married fellow scholar Stephanie Pickard in 1960 at Nottingham, after meeting her at a lecture given by Eduard Fraenkel at Corpus Christi College, Oxford, whose seminars he attended. He became a junior research fellow at St John's College from 1960 to 1963. His doctoral thesis, a commentary on Hesiod's Theogony, won the Conington Prize for the best classical dissertation of the year in 1965, and was edited as a printed book the following year. From the mid-sixties, West took especial interest in the relation of Greek literature to the Orient, and over several decades, culminating in his masterpiece The East Face of Helicon (1997), defended his view that Greek literature derives significant influences and inspiration from Near Eastern literature. He took up a position as tutorial fellow at University College, a position he filled from 1963 to 1974. In 1973 he became the second youngest person to be elected a Fellow of the British Academy, at the age of 35. He obtained a chair at Royal Holloway and Bedford New College, which he held from 1974 until 1991, when he became a fellow of All Souls College. West retired formally in 2004, but remained active in All Souls until the end of his life.
Agricultural and tropical regions report more snakebites than anywhere else. In the United States, those bitten are typically male and between 17 and 27 years of age. Children and the elderly are the most likely to die.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.